CoChat

Evaluation of the Impact of Mobile Health App Vitadio in Patients With Type 2 Diabetes: Randomized Controlled Trial

Open access

Published version of a preprint

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index; 24 of the 37 sources its claims cite were checked for support.

Abstract

Background: Effective diabetes management requires a multimodal approach involving lifestyle changes, pharmacological treatment, and continuous patient education. Self-management demands can be overwhelming for patients, leading to lowered motivation, poor adherence, and compromised therapeutic outcomes. In this context, digital health apps are emerging as vital tools to provide personalized support and enhance diabetes management and clinical outcomes. Objective: This study evaluated the impact of the digital health application Vitadio on glycemic control in patients with type 2 diabetes mellitus (T2DM). Secondary objectives included evaluating its effects on cardiometabolic parameters (weight, BMI, waist circumference, blood pressure, and heart rate) and self-reported measures of diabetes distress and self-management. Methods: In this 6-month, 2-arm, multicenter, unblinded randomized controlled trial, patients aged 18 years or older diagnosed with T2DM were randomly assigned (1:1) to an intervention group (IG) receiving standard diabetes care reinforced by the digital health app Vitadio or to a control group (CG) provided solely with standard diabetes care. Vitadio provided a mobile-based self-management support tool featuring educational modules, motivational messages, peer support, personalized goal setting, and health monitoring. The personal consultant was available in the app to provide technical support for app-related issues. The primary outcome, assessed in the intention-to-treat population, was a change in glycated hemoglobin (HbA1c) levels at 6 months. Secondary outcomes included changes in cardiometabolic measures and self-reported outcomes. Data were collected in 2 study centers: diabetologist practice in Dessau-Roßlau and the University of Dresden. Results: Between November 2022 and June 2023, a total of 276 patients were screened for eligibility, with 149 randomized to in intervention group (IG; n=73) and a control group (CG; n=76). The majority of participants were male (91/149, 61%). The dropout rate at month 6 was 19% (121/149). While both groups achieved significant HbA1c reduction at 6 months (IG: mean –0.8, SD 0.9%, P<.001; CG: mean –0.3, SD 0.7%, P=.001), the primary confirmatory analysis revealed statistically significant advantage of the IG (adjusted mean difference: –0.53%, SD 0.15, 95% CI –0.24 to –0.82; P<.001; effect size [Cohen d]=0.67, 95% CI 0.33-1). Significant between-group differences in favor of the IG were also observed for weight loss (P=.002), BMI (P=.001) and systolic blood pressure (P<.03). In addition, Vitadio users experienced greater reduction in diabetes-related distress (P<.03) and obtained more pronounced improvements in self-care practices in the areas of general diet (P<.001), specific diet (P<.03), and exercise (P<.03). Conclusions: This trial provides evidence for the superior efficacy of Vitadio in lowering the HbA1c levels in T2DM patients compared to standard care. In addition, Vitadio contributed to improvements in cardiometabolic health, reduced diabetes-related distress, and enhanced self-management, highlighting its potential as an accessible digital tool for comprehensive diabetes management. Trial Registration: German Clinical Trials Registry DRKS00027405; https://drks.de/search/de/trial/DRKS00027405.

Overview

CoChat Summary

TL;DR

In a 6-month, 2-arm, multicenter, unblinded randomized controlled trial, adding the Vitadio mobile health app to standard diabetes care significantly improved glycemic control in adults with type 2 diabetes compared with standard care alone. Vitadio users also showed greater improvements in several cardiometabolic and self-reported outcomes, including weight, BMI, systolic blood pressure, diabetes distress, and self-management.

Key findings

  • The primary outcome favored Vitadio: adjusted mean HbA1c difference at 6 months was –0.53% (SD 0.15, 95% CI –0.24 to –0.82; P<.001; Cohen d=0.67, 95% CI 0.33-1). Mean HbA1c reduction was –0.8% (SD 0.9; P<.001) in the intervention group vs –0.3% (SD 0.7; P=.001) in the control group.
  • Responder analysis showed more intervention participants reached HbA1c ≤7.0% (26% vs 8%; P=.004; OR 4.05, 95% CI 1.51-10.83), HbA1c ≤6.5% (11% vs 0%; P=.003; OR 19.6, 95% CI 1.11-346.06), and a ≥0.3% HbA1c reduction (77% vs 52%; P=.002; OR 3.04, 95% CI 1.5-6.17).
  • Significant between-group differences favoring Vitadio were reported for weight (MD –1.33 kg, 95% CI –2.25 to –0.42; P=.002), BMI (MD –0.47 kg/m², 95% CI –0.77 to –0.16; P=.001), systolic blood pressure (MD –7.8 mm Hg, 95% CI –13.45 to –2.16; P=.004), diabetes-related distress (PAID MD –6.21, 95% CI –10.58 to –1.85; P=.003), and SDSCA general diet (P<.001), specific diet (P=.007), and exercise (P=.02).
  • Vitadio was rated positively on most User Experience Questionnaire scales, with highest perspicuity (mean 1.42, SD 1.06); app-generated data showed average use on 95 (SD 63) days, 81% (35/43) completed all core education materials, and 81% (35/43) logged meals.

Methods

  • Design: 6-month, 2-arm, multicenter, unblinded randomized controlled trial; adults aged ≥18 years with T2DM and baseline HbA1c ≥7.5% to ≤11% were randomized 1:1 to Vitadio plus standard diabetes care or standard care alone.
  • Sample: 276 screened, 149 randomized (intervention n=73; control n=76); mean age 60.6 (SD 10.8) years, mean diabetes duration 11.7 (SD 7.5) years, 61% male; dropout at month 6 was reported as 19% (121/149).
  • Analysis: primary confirmatory analysis used intention-to-treat with a linear mixed-effects model for HbA1c over 3 visits, controlling for age, sex, insulin treatment, and diabetes duration; missing data imputed using reference-based multiple imputation; per-protocol and responder analyses also reported.

Limitations

  • Stated: blinding of participants and study physicians was not feasible due to the intervention’s nature; expectation bias in patient-reported outcomes cannot be fully excluded, though objective laboratory primary outcomes were considered unlikely to be affected.
  • Stated: attrition rates differed between study arms; imputation methods were used to minimize bias.
  • Evident from the text: the trial was conducted at two German study centers over 6 months, the sample was predominantly male (91/149, 61%), and longer-term durability beyond 6 months was not assessed.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.2196/68648

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Graphical representation of the study design.
Figure 1 Graphical representation of the study design.CC BY · PubMed Central
Figure 2 Screenshots of the Vitadio app: (a) photo-based nutrition diary with automatic feedback; (b) weekly diabetes education content; (c) peer support group for users.
Figure 2 Screenshots of the Vitadio app: (a) photo-based nutrition diary with automatic feedback; (b) weekly diabetes education content; (c) peer support group for users.CC BY · PubMed Central
Figure 3 Participant flow. ITT: intention to treat; PPS: per protocol set.
Figure 3 Participant flow. ITT: intention to treat; PPS: per protocol set.CC BY · PubMed Central

Verification

Claims the paper makes

11 Valid · 2 Not valid · 7 Not checked · 90 Own results and interpretations

64 more claims

Create a free account to see all 110 claims and to verify the 1 reference still open.

See all claims — free account
  • Probably not a substantial claim. 19
  • It may state two separate claims as one. 30

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

4 of 4

Citations

Cites

Show all 42 references

Metadata

Authors
Bretschneider, M. P., Kolasińska, A. B., Šomvárska, L., Klásek, J., Mareš, J., & Schwarz, P. E.
Affiliations
  • Technische Universität Dresden (DE)
  • Vidia (Czechia) (CZ)
  • German Center for Diabetes Research (DE)
Corresponding author
Bretschneider, Maxi Pia
Venue
Journal of Medical Internet Research
Published
2025-05-09
Volume
27
Pages
e68648
ISSN
1438-8871 (ISSN-L)
OpenAlex
W4410224886
Cited by
23
References
40
Citations by year
2026: 15 · 2025: 8
FWCI
17.05
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Journal of Medical Internet Research (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Bundesinstitut für Arzneimittel und Medizinprodukte
Topics
  • Health Sciences › Health Professions › General Health Professions › Mobile Health and mHealth Applications
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
type 2 diabetes, mobile health apps, glycemic control, HbA1c, diabetes self-management, diabetes distress, cardiometabolic parameters, peer support, goal setting, digital health interventions, patient education, medication adherence, blood pressure, waist circumference, body mass index, heart rate monitoring, remote patient monitoring
MeSH terms
Self-Management, Adult, Aged, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Male, Middle Aged, Self Care, Telemedicine, Mobile Applications

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Evaluation of the Impact of Mobile Health App Vitadio in Patients With Type 2 Diabetes: Randomized Controlled Trial. https://app.cochat.ai/papers/10.2196/68648
The paper
Bretschneider, M. P., Kolasińska, A. B., Šomvárska, L., Klásek, J., Mareš, J., & Schwarz, P. E. (2025). Evaluation of the Impact of Mobile Health App Vitadio in Patients With Type 2 Diabetes: Randomized Controlled Trial. Journal of Medical Internet Research. https://doi.org/10.2196/68648

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.